Entering text into the input field will update the search result below

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul. 06, 2022 9:13 AM ETCoherus BioSciences, Inc. (CHRS) Stock, SHJBF StockBy: Ravikash, SA News Editor

Anatomy of the mouth, throat and nose

SvetaZi/iStock via Getty Images

  • The U.S. Food and Drug Administration (FDA) accepted for review Coherus BioSciences (NASDAQ:CHRS) and Shanghai Junshi Biosciences' (OTCPK:SHJBF) resubmitted application seeking approval of toripalimab to treat a rare type of head and neck cancer.
  • The companies' biologics license

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.